Literature DB >> 24850290

Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.

Y Maesako1, A Okumura2, K Takeoka2, C Kishimori2, K Izumi1, Y Kamoda1, F Iioka1, T Akasaka1, H Ohno3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24850290     DOI： 10.1038/leu.2014.166

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  ALK fusion genes in children with atypical myeloproliferative leukemia.

Authors:  S Röttgers; M Gombert; A Teigler-Schlegel; K Busch; U Gamerdinger; R Slany; J Harbott; A Borkhardt
Journal:  Leukemia       Date:  2010-04-29       Impact factor: 11.528

2.  Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.

Authors:  Maxi Wass; Timo Behlendorf; Bärbel Schädlich; Anja Mottok; Andreas Rosenwald; Hans-Joachim Schmoll; Karin Jordan
Journal:  Eur J Haematol       Date:  2014-01-10       Impact factor: 2.997

3.  Overcoming drug resistance in ALK-rearranged lung cancer.

Authors:  Roman K Thomas
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

4.  Autosomal monosomies among 24,262 consecutive cytogenetic studies: prevalence, chromosomal distribution and clinicopathologic correlates of sole abnormalities.

Authors:  Sania Raza; Fareeda TaherNazerHussain; Mrinal Patnaik; Ryan Knudson; Daniel Van Dyke; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2011-04       Impact factor: 10.047

5.  Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

Authors:  Robert C Doebele; Amanda B Pilling; Dara L Aisner; Tatiana G Kutateladze; Anh T Le; Andrew J Weickhardt; Kimi L Kondo; Derek J Linderman; Lynn E Heasley; Wilbur A Franklin; Marileila Varella-Garcia; D Ross Camidge
Journal:  Clin Cancer Res       Date:  2012-01-10       Impact factor: 12.531

Review 6.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

7.  Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study.

Authors:  Yael P Mossé; Megan S Lim; Stephan D Voss; Keith Wilner; Katherine Ruffner; Julie Laliberte; Delphine Rolland; Frank M Balis; John M Maris; Brenda J Weigel; Ashish M Ingle; Charlotte Ahern; Peter C Adamson; Susan M Blaney
Journal:  Lancet Oncol       Date:  2013-04-16       Impact factor: 41.316

8.  Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

Authors:  Johannes M Heuckmann; Hyatt Balke-Want; Florian Malchers; Martin Peifer; Martin L Sos; Mirjam Koker; Lydia Meder; Christine M Lovly; Lukas C Heukamp; William Pao; Ralf Küppers; Roman K Thomas
Journal:  Clin Cancer Res       Date:  2012-08-21       Impact factor: 12.531

9.  Nup358/RanBP2 attaches to the nuclear pore complex via association with Nup88 and Nup214/CAN and plays a supporting role in CRM1-mediated nuclear protein export.

Authors:  Rafael Bernad; Hella van der Velde; Maarten Fornerod; Helen Pickersgill
Journal:  Mol Cell Biol       Date:  2004-03       Impact factor: 4.272

Review 10.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716
View more
  3 in total

1.  Crizotinib treatment for refractory pediatric acute myeloid leukemia with RAN-binding protein 2-anaplastic lymphoma kinase fusion gene.

Authors:  A Hayashi; R Tanoshima; S-I Tsujimoto; M Yanagimachi; M Takeuchi; K Sasaki; J Ikeda; R Kajiwara; S Ito; H Takahashi
Journal:  Blood Cancer J       Date:  2016-08-05       Impact factor: 11.037

Review 2.  The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors:  Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

3.  Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report.

Authors:  Brice Leyrat; Xavier Durando; Hugo Veyssiere; Maureen Bernadach
Journal:  Onco Targets Ther       Date:  2021-06-29       Impact factor: 4.147
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.